Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT. BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level.
最近，上海美蘭生物醫藥科技有限公司（“美蘭生物”）和恒瑞醫藥股份有限公司（“恒瑞醫藥”）簽署了戰略合作協議。合作方將重點關注新藥模式的臨床前評估，特別是ADC、小分子核酸和CGt（細胞基因治療）藥物。此次合作的目標是推進中國藥業板塊的創新，以在全球範圍內展開競爭。
The elevated commitment to collaboration between Medicilon and Hengrui Pharma builds upon the solid foundation from years of experience and well-established trust. The organizations plan to integrate Medicilon's preclinical R&D expertise with Hengrui Pharma's innovative strategies and market influence. Medicilon will leverage its technological advantages in drug discovery and development to provide Hengrui Pharma with a range of preclinical services, focusing on efficacy testing, pharmacokinetics, and toxicology studies for new drug modalities. Medicilon and Hengrui Pharma will combine efforts to generate breakthroughs in pharmaceutical therapies.
美蘭生物和恒瑞醫藥加強合作的承諾建立在多年的經驗和良好信任的堅實基礎之上。合作雙方計劃將美蘭生物的臨床前研發專業知識與恒瑞醫藥的創新戰略和市場影響結合起來。美蘭生物將利用其在藥物發現和開發方面的技術優勢，爲恒瑞醫藥提供一系列臨床前服務，重點是新藥模式的療效測試、藥代動力學和毒理學研究。美蘭生物和恒瑞醫藥將共同努力實現製藥療法的突破。
The atmosphere of the exchange was enthusiastic and congenial. Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang, along with other executives, visited Medicilon's Pudong Chuansha Park. They were welcomed by Medicilon's CEO Chunlin Chen and key team members.
交流氣氛熱烈友好。恒瑞醫藥副總經理兼全球研發總裁張連山先生與其他高管一同訪問了美蘭生物的浦東川沙園區。他們受到了美蘭生物CEO陳春林博士和重要團隊成員的熱情歡迎。
During the visit, Medicilon's R&D Team introduced their one-stop preclinical services platform for pharmaceutical R&D. They highlighted the Medicilon's capabilities and technical strengths in safety evaluation, pharmacology, and pharmacokinetics, with special attention to PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and CGT.
在訪問期間，美蘭生物的研發團隊介紹了其一站式藥物研發臨床前平台，強調了藥物安全評價、藥理學和藥代動力學等方面的核心技術和實力，特別關注了PROTAC、ADC、核酸、雙特異性抗體、肽類、疫苗和CGt。
Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang stated, "Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning."
恒瑞醫藥副總經理兼全球研發總裁張連山表示：“美蘭生物在這個領域擁有彈性創新和服務品質，是值得信賴的CRO合作伙伴。恒瑞醫藥與美蘭生物之間的合作不僅承認了過去的成就，更代表了未來合作潛力和前瞻性戰略規劃的深入探討。”
Medicilon's Founder & CEO Chunlin Chen stated, "Medicilon and Hengrui Pharma firmly believe that, through close collaboration, the process of drug R&D will be accelerated in the future, contributing to the innovative development of the global pharmaceutical industry."
美蘭生物創始人兼CEO陳春林表示：“美蘭生物和恒瑞醫藥堅信，通過密切合作，未來的藥物研發過程將得到加速，從而促進全球製藥行業的創新發展。”
Website:
網址：
SOURCE Medicilon Inc.
來源：美蘭生物
